Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia

Background: Mutations of the transforming growth factor β (TGFβ) receptor components ENDOGLIN and ALK-1 cause the autosomal dominant vascular disorder hereditary haemorrhagic telangiectasia (HHT). Heterozygous mutations of the type II receptor BMPR2 underlie familial primary pulmonary hypertension. Objective: To investigate kindreds presenting with both pulmonary hypertension and HHT. Methods: Probands and families were identified by specialist pulmonary hypertension centres in five countries. DNA sequence analysis of ALK-1, ENDOGLIN, and BMPR2 was undertaken. Cellular localisation was investigated by heterologous overexpression of mutant constructs in both BAEC and HeLa cells. The impact of a novel sequence variant was assessed through comparative analysis and computer modelling. Results: Molecular analysis of 11 probands identified eight missense mutations of ALK-1, one of which was observed in two families. Mutations were located within exons 5 to 10 of the ALK-1 gene. The majority of ALK-1 mutant constructs appeared to be retained within the cell cytoplasm, in the endoplasmic reticulum. A novel GS domain mutation, when overexpressed, reached the cell surface but is predicted to disrupt conformational changes owing to loss of a critical hydrogen bond. Two novel missense mutations were identified in ENDOGLIN. Conclusions: The association of pulmonary arterial hypertension and HHT identifies an important disease complication and appears most common among subjects with defects in ALK-1 receptor signalling. Future studies should focus on detailed molecular analysis of the common cellular pathways disrupted by mutations of ALK-1 and BMPR2 that cause inherited pulmonary vascular disease.

[1]  L. Korniszewski,et al.  [Genetics of primary pulmonary hypertension]. , 2004, Polskie Archiwum Medycyny Wewnetrznej.

[2]  S. Mundlos,et al.  Mutations in bone morphogenetic protein receptor 1B cause brachydactyly type A2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Bonneau,et al.  Visceral manifestations in hereditary haemorrhagic telangiectasia type 2 , 2003, Journal of medical genetics.

[4]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[5]  C. Deber,et al.  Disease-associated mutations in conserved residues of ALK-1 kinase domain , 2003, European Journal of Human Genetics.

[6]  C. Mummery,et al.  Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. , 2003, Cardiovascular research.

[7]  S. Hodge,et al.  BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives , 2002, European Respiratory Journal.

[8]  E. Buscarini,et al.  Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia , 2002, Journal of medical genetics.

[9]  N. Rudarakanchana,et al.  Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. , 2002, Human molecular genetics.

[10]  F. Tsai,et al.  Mutation analysis of a family with hereditary hemorrhagic telangiectasia associated with hepatic arteriovenous malformation. , 2001, Journal of the Formosan Medical Association = Taiwan yi zhi.

[11]  J Kuriyan,et al.  The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. , 2001, Molecular cell.

[12]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[13]  K. Brusgaard,et al.  Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families. , 2001, American journal of medical genetics.

[14]  M. Humbert,et al.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.

[15]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[16]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[17]  S. Hallam,et al.  Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. , 2000, American journal of medical genetics.

[18]  N. Pece-Barbara,et al.  Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. , 2000, Human molecular genetics.

[19]  A. Guttmacher,et al.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). , 2000, American journal of medical genetics.

[20]  Morgan Huse,et al.  Crystal Structure of the Cytoplasmic Domain of the Type I TGF β Receptor in Complex with FKBP12 , 1999, Cell.

[21]  J. Wrana,et al.  Endoglin Is an Accessory Protein That Interacts with the Signaling Receptor Complex of Multiple Members of the Transforming Growth Factor-β Superfamily* , 1999, The Journal of Biological Chemistry.

[22]  D. W. Johnson,et al.  The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. , 1997, American journal of human genetics.

[23]  D. W. Johnson,et al.  Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.

[24]  J. Massagué,et al.  Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors , 1993, Cell.

[25]  M. Porteous,et al.  Hereditary haemorrhagic telangiectasia: a clinical analysis. , 1992, Journal of medical genetics.

[26]  R. Sapru,et al.  Pulmonary hypertension in patients with pulmonary arteriovenous fistulae. , 1969, British heart journal.

[27]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[28]  S. Kenwrick,et al.  Disease-associated mutations in L1 CAM interfere with ligand interactions and cell-surface expression. , 2002, Human molecular genetics.

[29]  J. Doré,et al.  Transforming growth factor beta receptor signaling and endocytosis are linked through a COOH terminal activation motif in the type I receptor. , 2001, Molecular Biology of the Cell.

[30]  D. W. Johnson,et al.  Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Mutations in brief no. 164. Online. , 1998, Human mutation.

[31]  D. Marchuk,et al.  Novel missense and frameshift mutations in the activin receptor‐like kinase‐1 gene in hereditary hemorrhagic telangiectasia , 1998 .

[32]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[33]  J. Newman,et al.  Familial primary pulmonary hypertension: clinical patterns. , 1984, The American review of respiratory disease.